Remdesivir for the Treatment of Covid-19— Final Report

Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 and the Middle East respiratory syndrome (MERS-CoV), was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro. In addition, in nonhuman primate studies, remdesivir initiated 12 hours after inoculation with MERS-CoV reduced lung virus levels and lung damage. our data shows that remdesivir was siperior to placebo in shortening the time to recovery in adults who were hospitalized with covid-19 and had evidence of lower respitatory tract infection.

Remdesivir for the Treatment of Covid-19 — Final Report
Size: 559 KB